NCIt related terms : Anti-PD-1 Monoclonal Antibody IBI308;
NCIt definition : A recombinant human monoclonal antibody directed against the negative immunoregulatory
human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential
immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab
binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell
death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation
of PD-1 and its downstream signaling pathways. This may restore immune function through
the activation of both T-cells and T-cell-mediated immune responses against tumor
cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed
on activated T-cells, negatively regulates T-cell activation and effector function
when activated by its ligands; it plays an important role in tumor evasion from host
immunity.;
UNII : 8FU7FQ8UPK;
CAS number : 2072873-06-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2072873-06-2
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;